GALDERMA LABS
PharmaGALDERMA LABS is a pharmaceutical company focused on Dermatology, Immunology. Key products include EPIDUO FORTE.
GALDERMA LABS at a Glance
- Strong track record with 92% execution quality across 149 trials
- Leading 5 drug targets across portfolio
GALDERMA LABS's Key Drugs
GALDERMA LABS's core commercial portfolio centers on EPIDUO FORTE, spanning Dermatology and Immunology — its most strategically important drugs approved in the last 15 years.
GALDERMA LABS's Recent FDA Approvals
New NDA/BLA approvals for GALDERMA LABS over the last two years — novel drugs only, excluding generics and label supplements.
GALDERMA LABS's Therapeutic Areas
GALDERMA LABS's approved drugs and pipeline span 2 therapeutic areas, led by Dermatology and Immunology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
GALDERMA LABS's Top Competitors
GALDERMA LABS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
GALDERMA LABS Pipeline Snapshot
Active clinical trials for GALDERMA LABS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • EPIDUO FORTE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 44/49 completed
- • Speed: 10 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2004-02-05
- Latest
- 2022-04-27
- Applications
- 2
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges